Repligen (NASDAQ:RGEN) Sets New 12-Month High – Still a Buy?

Repligen Corporation (NASDAQ:RGEN) hit a new 52-week high during trading on Wednesday . The company traded as high as $179.87 and last traded at $177.8660, with a volume of 224928 shares trading hands. The stock had previously closed at $166.15.

Wall Street Analysts Forecast Growth

RGEN has been the subject of a number of recent research reports. HSBC cut their price target on Repligen from $170.00 to $150.00 and set a “buy” rating for the company in a research note on Wednesday, June 3rd. Wolfe Research began coverage on Repligen in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 price objective on the stock. Zacks Research upgraded Repligen from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 30th. Weiss Ratings raised shares of Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, August 13th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Repligen from $165.00 to $175.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $166.43.

Repligen Trading Up 5.9%

The company’s fifty day moving average is $144.29 and its 200-day moving average is $131.18. The company has a current ratio of 9.05, a quick ratio of 7.64 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $9.93 billion, a P/E ratio of 242.26, a P/E/G ratio of 3.04 and a beta of 1.03.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The firm had revenue of $204.13 million for the quarter, compared to the consensus estimate of $201.59 million. During the same quarter last year, the firm posted $0.26 EPS. The business’s quarterly revenue was up 11.9% on a year-over-year basis. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, sell-side analysts anticipate that Repligen Corporation will post 2.06 earnings per share for the current fiscal year.

Insider Buying and Selling at Repligen

In related news, CFO Jason K. Garland sold 733 shares of the business’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the completion of the transaction, the chief financial officer owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. The trade was a 3.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC acquired a new stake in shares of Repligen in the first quarter worth $262,000. Jones Financial Companies Lllp raised its stake in Repligen by 3,850.6% during the 1st quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company’s stock valued at $814,000 after purchasing an additional 6,238 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Repligen by 16.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company’s stock valued at $18,067,000 after purchasing an additional 20,375 shares during the last quarter. Bank of Nova Scotia boosted its holdings in Repligen by 88.0% in the 2nd quarter. Bank of Nova Scotia now owns 31,747 shares of the biotechnology company’s stock valued at $3,951,000 after purchasing an additional 14,860 shares during the period. Finally, Daiwa Securities Group Inc. boosted its holdings in Repligen by 29.7% in the 2nd quarter. Daiwa Securities Group Inc. now owns 31,194 shares of the biotechnology company’s stock valued at $3,880,000 after purchasing an additional 7,148 shares during the period. 97.64% of the stock is owned by institutional investors.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.